OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical and Experimental Dermatology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Erythema multiforme‐like eruption in patients with COVID‐19 infection: clinical and histological findings	115
Two cases of COVID‐19 presenting with a clinical picture resembling chilblains: first report from the Middle East	100
Clinical and histological characterization of vesicular COVID‐19 rashes: a prospective study in a tertiary care hospital	88
COVID‐19 vaccine‐induced Stevens–Johnson syndrome	55
Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice	55
Treatment options for leishmaniasis	54
WhatsApp messenger as a teledermatology tool during coronavirus disease (COVID‐19): from bedside to phone‐side	52
Skin manifestations of COVID‐19 in children: Part 1	52
Reduction in skin cancer diagnoses in the UK during the COVID‐19 pandemic	46
Potential use of turmeric in COVID‐19	42
Irritant contact dermatitis in healthcare workers as a result of the COVID‐19 pandemic: a cross‐sectional study	41
A cutoff value for the Systemic Immune‐Inflammation Index in determining activity of Behçet disease	39
COVID‐19 vaccination and patients with psoriasis under biologics: real‐life evidence on safety and effectiveness from Italian vaccinated healthcare workers	38
Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID‐19 vaccine	38
Janus kinase inhibitors for atopic dermatitis: a promising treatment modality	38
De novo generalized pustular psoriasis following Oxford‐AstraZeneca COVID‐19 vaccine	38
Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA‐based or adenoviral vector‐based SARS‐CoV‐2 vaccination	36
Skin manifestations of COVID‐19 in children: Part 2	36
Line‐field optical coherence tomography: in vivo diagnosis of basal cell carcinoma subtypes compared with histopathology	35
Asymmetrical cutaneous vasculitis following COVID‐19 vaccination with unusual eosinophil preponderance	34
Facial dermatoses in the general population due to wearing of personal protective masks during the COVID‐19 pandemic: first observations after lockdown	34
Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’	33
Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns	31
Telemedicine and support groups could be used to improve adherence to treatment and health‐related quality of life in patients affected by inflammatory skin conditions during the COVID‐19 pandemic	31
The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience	31

Chilblain‐like lesions: a case series of 41 patients during the COVID‐19 pandemic	29
Line‐field confocal optical coherence tomography for actinic keratosis and squamous cell carcinoma: a descriptive study	29
Vitiligo in a COVID‐19‐vaccinated patient with ulcerative colitis: coincidence?	29
Successful treatment with dupilumab of an adult with Netherton syndrome	28